Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: Exhaled particle analysis
- Registration Number
- NCT01088633
- Lead Sponsor
- Fraunhofer-Institute of Toxicology and Experimental Medicine
- Brief Summary
This study is aiming at evaluating the characteristics of particle emission in subjects with different stages of chronic obstructive pulmonary disease (COPD) compared with healthy smokers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
-
Male or female subjects, aged ≥ 18 years
-
COPD: Physician diagnosis of chronic obstructive pulmonary disease (COPD GOLD I to IV according to GOLD guidelines)9
-
Healthy smokers: current smokers with a history of at least 10 packyears and no signs of bronchial obstruction in spirometry (FEV1 >= 80% pred, FEV1/FVC >= 70%)
-
Able and willing to give written informed consent
-
Women will be considered for inclusion if they are:
- not pregnant, as confirmed by pregnancy test, and not nursing
- of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit)
- of childbearing potential and using a highly effective method of contraception during the entire study (vasectomized partner, sexual abstinence) - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study , implants, injectables, combined oral contraceptives, hormonal IUDs, or double-barrier methods, i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap)
-
Available to complete all study measurements
- History of lower respiratory tract infection four weeks prior to the informed consent visit
- Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to tuberculosis, bronchiectasis or cystic fibrosis)
- History of drug or alcohol abuse
- Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
- Inability to abstain from bronchodilators according to section 8.2 (Prohibited medication)
- Risk of non-compliance with study procedures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Exhaled particle analysis Exhaled particle analysis -
- Primary Outcome Measures
Name Time Method Characterization of particles in exhaled breath of subjects with COPD compared with healthy smokers. within one day At visit 2, the exhaled particle analysis will be performed. These measurements will be repeated after 2 hours on the same day.
Visit 3:
After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Fraunhofer Institute for Toxicolocy
🇩🇪Hannover, Niedersachsen, Germany